By Counterforce Health Team in Synagis (palivizumab) —

The Requirements Checklist to Get Synagis (Palivizumab) Covered by Aetna (CVS Health) in Florida

Answer Box: Getting Synagis Covered by Aetna (CVS Health) in Florida

Synagis (palivizumab) requires prior authorization from Aetna (CVS Health) for high-risk infants meeting specific AAP criteria. The fastest path: (1) Have your pediatric specialist complete Aetna's Synagis PA form with detailed clinical documentation, (2) Submit via Aetna's provider portal or designated fax with supporting records, (3) Follow up within 5-7 business days for standard review or 72 hours for expedited cases. If denied, you have 180 days to appeal internally, then can request Florida external review within 4 months. Start today by calling Aetna member services at the number on your insurance card to confirm current PA requirements and forms.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding and Billing Requirements
  5. Documentation Packet
  6. Submission Process
  7. Specialty Pharmacy Routing
  8. After Submission: Tracking and Follow-up
  9. Common Denial-Prevention Tips
  10. Appeals Process for Florida
  11. Printable Checklist

Who Should Use This Checklist

This checklist is designed for families and healthcare providers seeking Synagis (palivizumab) coverage through Aetna (CVS Health) plans in Florida. Use this guide if your child:

  • Is under 24 months old and at high risk for severe RSV infection
  • Has been recommended for RSV prophylaxis by a pediatric specialist
  • Needs monthly Synagis injections during RSV season (typically November-March)
  • Has Aetna coverage administered through CVS Health networks

Expected outcome: Following this checklist increases your chances of first-time approval and reduces delays that could leave your high-risk infant unprotected during RSV season.

Member & Plan Basics

Verify Active Coverage

  • Confirm Aetna member ID and current coverage status
  • Check if your plan uses CVS Caremark or CVS Specialty for specialty medications
  • Verify pediatric coverage and any deductible requirements
  • Confirm your child's eligibility for the current RSV season

Plan Type Considerations

Aetna offers various plan types in Florida, each with specific requirements:

  • Commercial plans: Standard PA process through CVS Caremark
  • Medicaid managed care: May have additional state-specific criteria
  • Medicare Advantage: Follows Medicare Part B guidelines for covered members
  • ACA marketplace plans: Subject to Florida external review rights
Tip: Call the member services number on your insurance card to confirm which specialty pharmacy network manages Synagis for your specific plan.

Clinical Criteria Requirements

Aetna requires prior authorization for all Synagis use and restricts coverage to high-risk infants who cannot appropriately receive Beyfortus (nirsevimab). Your child must meet all general conditions plus one high-risk category.

General PA Conditions

  • All Synagis requests require PA and medical necessity review
  • Child has not received Beyfortus for the current RSV season
  • Documented reason why Synagis is needed instead of Beyfortus

High-Risk Categories (Must Meet One)

Extreme Prematurity

  • Born <29 weeks 0 days gestational age
  • <12 months of age at RSV season start

Chronic Lung Disease (CLD) - First RSV Season

  • Born <32 weeks 0 days gestation
  • <12 months of age at RSV season start
  • Required >21% supplemental oxygen for ≥28 days after birth

Hemodynamically Significant Congenital Heart Disease

  • <12 months of age at RSV season start
  • Receiving medications for heart failure OR
  • Moderate to severe pulmonary hypertension OR
  • Requires cardiac surgery OR
  • Cyanotic heart disease with cardiology consultation

Second RSV Season Eligibility

  • <24 months of age at time of request
  • CLD with continued medical therapy in past 6 months OR
  • CHD status post heart transplant OR
  • Profoundly immunocompromised (chemo/transplant) OR
  • Cystic fibrosis with high-risk features

Season and Dosing Limits

  • Maximum 5-month duration per RSV season
  • Authorization not to exceed March 31 of RSV season
  • 15 mg/kg IM once monthly dosing
  • Off-season requests require CDC surveillance justification

Coding and Billing Requirements

ICD-10 Diagnosis Codes

Primary diagnosis (required):

  • Z29.11 – Encounter for prophylactic immunotherapy for RSV

Supporting risk-factor codes:

  • P07.21-P07.26: Low birth weight newborn
  • P07.31-P07.39: Preterm newborn by gestational age
  • P27.1: Bronchopulmonary dysplasia
  • Q20-Q26 series: Congenital heart defects

HCPCS and Administration Codes

  • J2504 – Injection, palivizumab, per 15 mg
  • 96372 – IM injection administration
  • Calculate units: total mg given ÷ 15 mg (rounded per payer rules)
Note: Link all billing lines to Z29.11 plus applicable risk-factor ICD-10 codes for proper reimbursement.

Documentation Packet

Provider Note Elements

Your pediatric specialist's clinical note must include:

Patient Demographics

  • Gestational age at birth and birth weight
  • Current chronological age at RSV season start
  • Current weight in kg for dosing calculations

Risk Documentation

  • Primary qualifying condition with severity details
  • NICU course and ventilation history (if applicable)
  • Current medications for CLD or CHD with dates
  • Cardiology or pulmonology consultation notes

Treatment Plan

  • Planned number of doses (up to 5 per season)
  • Administration schedule and location
  • Monitoring plan during treatment

Letter of Medical Necessity Components

For complex cases or appeals, include a formal letter addressing:

  1. Clinical justification: Why this child meets AAP high-risk criteria
  2. Risk assessment: Consequences of RSV infection for this patient
  3. Treatment rationale: Why Synagis is medically necessary
  4. Guideline alignment: Reference to AAP RSV prophylaxis recommendations
  5. Alternative considerations: Why Beyfortus is not appropriate

Required Attachments

  • Recent specialist consultation notes
  • NICU discharge summary (if applicable)
  • Current growth chart
  • Relevant imaging (echocardiogram, chest X-ray)
  • Current medication list with dosing

Submission Process

Correct Form and Portal Access

  1. Obtain current Aetna Synagis PA form from provider portal or member services
  2. Complete all required fields – incomplete forms cause automatic delays
  3. Use Aetna provider portal when possible for faster processing
  4. Alternative submission: Fax to designated PA department (verify current number)

Common Rejection Fields

Avoid these frequent submission errors:

  • Missing gestational age or birth weight
  • Incomplete current weight for dosing
  • Missing specialist signature or NPI
  • Unclear risk category documentation
  • Missing Beyfortus status explanation

Submission Timeline

  • Standard review: 5-7 business days after complete submission
  • Expedited review: 72 hours for urgent cases during RSV season
  • Best practice: Submit 60-90 days before expected RSV season start

Specialty Pharmacy Routing

CVS Specialty Enrollment

Most Aetna plans require Synagis dispensing through CVS Specialty:

  1. Prescriber initiates enrollment using CVS Specialty RSV form
  2. Include PA authorization for CVS to manage approval process
  3. Provide delivery preferences and administration site details
  4. Confirm benefit verification and any copay requirements

Delivery Coordination

  • Designate delivery address (clinic, home health, or patient home)
  • Arrange for refrigerated medication receipt
  • Coordinate with administration provider
  • Schedule monthly delivery to match dosing schedule
Important: Some Florida Medicaid plans designate CVS Caremark Specialty as the exclusive Synagis provider and handle enrollment automatically once treatment is authorized.

After Submission: Tracking and Follow-up

Confirmation and Status Checks

  • Record PA confirmation number
  • Schedule follow-up call in 3-5 business days
  • Monitor Aetna provider portal for status updates
  • Keep copies of all submitted documentation

Response Timeline Expectations

  • Approval: Receive written authorization with approved doses and dates
  • Denial: Detailed explanation of denial reason and appeal rights
  • Pending: Request for additional information – respond promptly

Documentation During Treatment

For each monthly dose, record:

  • Date and administration site
  • Current weight and calculated dose
  • Any adverse reactions
  • Continued medical necessity factors

Common Denial-Prevention Tips

Five Critical Pitfalls to Avoid

  1. Incomplete risk documentation
    • Problem: Vague diagnosis without severity details
    • Solution: Include specific clinical data (oxygen requirements, cardiac function, growth parameters)
  2. Missing Beyfortus explanation
    • Problem: No justification for Synagis over nirsevimab
    • Solution: Document contraindication, supply issues, or high-risk category requiring Synagis
  3. Age/season timing errors
    • Problem: Child exceeds age limits or season hasn't started
    • Solution: Verify current age at season start and local RSV activity
  4. Inadequate specialist involvement
    • Problem: Primary care provider without specialist consultation
    • Solution: Obtain cardiology or pulmonology evaluation and recommendation
  5. Prior authorization expiration
    • Problem: Attempting to continue previous season's approval
    • Solution: Submit new PA for each RSV season – approvals don't carry over
Pro Tip: When in doubt, request a peer-to-peer review with an Aetna medical director who can clarify specific criteria questions.

Appeals Process for Florida

Internal Appeal Rights

If Aetna denies your Synagis request, you have 180 days from the denial notice to file an internal appeal:

Standard Internal Appeal

  • Submit written appeal with supporting clinical documentation
  • Include updated specialist letter addressing denial reasons
  • Expected decision timeline: 30-45 days

Expedited Appeal

  • Available when delay could seriously jeopardize health
  • Particularly relevant during active RSV season
  • Decision timeline: 72 hours or less

Florida External Review

After exhausting internal appeals, Florida residents can request independent external review:

Eligibility Requirements

  • Completed all internal appeal levels
  • Denial based on medical necessity (not benefit exclusion)
  • Request filed within 4 months of final internal denial

Filing Process

  • Submit request to Florida Department of Financial Services
  • Include all denial letters and clinical records
  • No cost to consumer for external review
  • Decision is binding on Aetna

Contact Information

  • Florida Insurance Consumer Helpline: 1-877-MY-FL-CFO (1-877-693-5236)
  • Online complaint portal available through Florida Department of Financial Services

When to Escalate

Consider professional assistance if:

  • Child is extremely high-risk or medically fragile
  • Multiple denials despite meeting clear criteria
  • Urgent need during peak RSV season
  • Complex medical conditions requiring specialized advocacy

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Our platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements by identifying denial reasons and drafting point-by-point rebuttals aligned to payer policies. For high-stakes cases like Synagis denials in vulnerable infants, having expert support can make the difference between approval and dangerous delays in critical preventive care.

Printable Checklist

Pre-Submission Checklist

Patient Information

  • Aetna member ID and current coverage verified
  • Gestational age at birth: _____ weeks
  • Current age at RSV season start: _____ months
  • Current weight: _____ kg (date: ______)

Clinical Documentation

  • Primary high-risk condition documented with severity
  • Specialist consultation note within 6 months
  • NICU records (if applicable)
  • Current medication list with dates
  • Beyfortus status explained

Submission Package

  • Complete Aetna Synagis PA form
  • Letter of medical necessity (if needed)
  • All required attachments
  • Specialist signature and NPI
  • Submission method confirmed (portal/fax)

Follow-up Plan

  • Confirmation number recorded: __________
  • Status check scheduled for: ___________
  • CVS Specialty enrollment initiated (if required)
  • Delivery arrangements confirmed

From Our Advocates

We've seen many Synagis denials overturned when families and providers work together to present comprehensive clinical documentation that clearly maps the child's condition to established AAP criteria. The key is often in the details – showing not just that a child was premature, but documenting the specific respiratory support needed and ongoing medical management. These cases remind us that persistence and thorough preparation can protect vulnerable infants during RSV season.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare providers and insurance representatives for guidance specific to your situation.

Sources & Further Reading

For additional support with complex prior authorization challenges, Counterforce Health provides specialized assistance in navigating insurance denials and developing evidence-based appeals for specialty medications like Synagis.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.